Prot #M14-032: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Project: Research project

Project Details

StatusFinished
Effective start/end date12/18/14 → 12/31/22

Funding

  • INC Research, LLC (Prot #M14-032)
  • AbbVie Inc. (Prot #M14-032)